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To the Editor: Based on the findings that Neurog3-null mice
fail to develop pancreatic islets [1] and lack enteroendocrine
cells [2], this basic helix-loop-helix (bHLH) transcription
factor is considered to be essential for differentiation of endo-
crine cells both in the pancreas and in the gut [3]. Limited data
from human fetuses suggest that transient expression of
NEUROG3 in pancreatic progenitor cells from approximately
7 to 8 weeks post conception is followed by beta cell differ-
entiation and immature islet formation by week 12 of fetal
development [4, 5].
Homozygous loss-of-function mutations in NEUROG3
were first identified in patients with a rare form of congenital
malabsorpt ive diarrhoea that was due to enteric
anendocrinosis [6]. Unexpectedly, the patients did not present
with neonatal diabetes, suggesting that pancreatic islet devel-
opment was at least partially spared, although they developed
diabetes during late childhood. The authors hypothesised that
an unidentified factor might compensate for the absence of
functional neurogenin 3 (NEUROG3) and result in the pro-
duction of some functional beta cells. Further studies showed
that the reported mutations were hypomorphic rather than null
mutations. Therefore, differences in NEUROG3 gene dosage
requirements could explain the observed differential effect on
the intestinal and pancreatic phenotypes [7].
We recently identified biallelic null NEUROG3 mutations
in a patient with enteric anendocrinosis and permanent neo-
natal diabetes [8]. Although pancreatic tissue was not avail-
able for direct analysis, the presence of detectable blood
C-peptide indicated that there was some endogenous insulin
production at 4.5 years of age. Similar findings were later
reported in a different patient [9]. Consequently, we
hypothesised that, despite the pivotal role of Neurog3 in
pancreatic endocrine development in mice, complete
NEUROG3 deficiency does not necessarily imply an absolute
insulin deficiency in humans and, therefore, affected patients
may present with diabetes at any age.
To test this hypothesis, the single coding exon of
NEUROG3 was amplified and sequenced from genomic
DNA as previously described [8] in a further three probands
with congenital malabsorptive diarrhoea and diabetes, regard-
less of the age at diagnosis of the latter. This study was
conducted in accordance with the Declaration of Helsinki
and approved by the local ethics committee. Written informed
consent was obtained from the parents/guardians of the pa-
tients. Previously described homozygous missense mutations
were identified in the three cases and a non-diabetic sibling of
proband 3. Clinically unaffected siblings of probands 1 and 2
(one each) were unavailable for evaluation. Genetic findings
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and the most significant clinical features of these patients are
depicted in Table 1, along with similar data from all previous
case reports on children with biallelic NEUROG3 mutations
for comparison [6, 8–11]. Early-onset severe malabsorptive
diarrhoea was a common finding in the 11 patients, with
enteric anendocrinosis demonstrated in all cases where this
condition was investigated on intestinal biopsies. Absence of
enteroendocrine cells was not specifically investigated in any
of the four patients included in this study, but it has previously
been reported in patients with the same NEUROG3mutations
[6, 8]. Typically, the intestinal failure requires long-term par-
enteral nutrition initially, but oral feedings are increasingly
tolerated and parenteral nutrition can eventually be
discontinued. Low fecal elastase or trypsin levels have been
reported in some but not all cases, suggesting that pancreatic
exocrine insufficiency represents a functional defect second-
ary to a lack of cholecystokinin and secretin, the enteric
hormones that stimulate pancreatic exocrine secretion [10].
No evident genotype–phenotype correlation exists between
NEUROG3 mutations and pancreatic endocrine function.
NEUROG3 deficiency can lead to a number of different
phenotypes of diabetes, including permanent neonatal diabe-
tes, relapsing transient neonatal diabetes and childhood-onset
permanent diabetes. In either case, insulin production is par-
tially spared, as indicated by detectable, although relatively
low, C-peptide levels. Furthermore, none of the diabetic pa-
tients has ever presented with severe hyperglycaemia or keto-
sis, not even during acute intercurrent illness, which also
supports the persistence of some residual endogenous insulin
production. This relative insulin deficiency might be due in
part to a lack of incretin hormones (glucagon-like peptide 1,
glucose-dependent insulinotropic peptide) from the gut, a
hypothesis that has not been tested in NEUROG3-deficient
patients so far. However, diabetes does not universally present
during childhood or young adulthood, as evidenced by the
non-diabetic 23-year-old male patient, although it might de-
velop later on. In addition, the same genotype can cause
different diabetic phenotypes both between and within kin-
dreds. Overall, the data available suggest that either genetic or
non-genetic modifiers are likely to play a role in the pene-
trance and expressivity of diabetes in NEUROG3 biallelic
mutation carriers.
The presence of some residual endogenous insulin secre-
tion in patients with NEUROG3 deficiency suggests that, in
contrast to mice [3], a redundant NEUROG3-independent
pancreatic endocrine developmental pathway might exist in
humans so that NEUROG3 is not absolutely required for
differentiation of pancreatic progenitors into islet cell precur-
sors. In this sense, it has recently been reported that ASCL1B,
another bHLH transcriptor factor, initiates the endocrine cell
differentiation programme instead of NEUROG3 in zebrafish
[12]. Further research in this area will help clarify the exact
role of NEUROG3 in human pancreatic development.
In summary, NEUROG3 deficiency produces a rare clini-
cal syndrome characterised by severe malabsorptive diarrhoea
from early life and mild diabetes with a variable age of onset.
This finding suggests that NEUROG3 is important but not
essential for beta cell development and function in humans.
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